Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00367094
- Lead Sponsor
- Novartis
- Brief Summary
This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult Chinese patients with mild to moderate essential hypertension. Patients whose blood pressure is not adequately controlled with benazepril monotherapy during a 4 week run-in period will be randomly allocated to double blind treatment over 8 weeks with either a combination of benazepril/hydrochlorothiazide per day or continuation of benazepril per day.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 296
Inclusion Criteria
- Male or female patients, age 18 or older
- Given informed consent
- Diagnosed as having mild to moderate essential hypertension
Read More
Exclusion Criteria
- Severe hypertension
- Significant preexisting cardiovascular and cerebrovascular disease
- Diabetes mellitus type 1 or poorly controlled diabetes mellitus type II
- Advanced renal impairment
Other protocol-defined inclusion/exclusion criteria may apply.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change in diastolic blood pressure from baseline to week 8
- Secondary Outcome Measures
Name Time Method Change in systolic blood pressure from baseline to week 8 Proportion of patients with blood pressure less than 140/90 mmHg at week 8 Ambulant blood pressure monitoring profiles at baseline and week 8
Trial Locations
- Locations (1)
Novartis
🇨🇳Beijing, China